The shift from blockbuster drugs to more targeted biologics has left contract manufacturers struggling to adapt. The smaller batch sizes for biologics, gene therapies, and personalized medicines require a different strategy if manufacturers are going to maintain their efficiency and keep costs under control. One option they’re exploring is ready-to-use (RTU) packaging. But, while RTU…